Hematotoxicology

Hematotoxicology is the branch of toxicology focused on adverse effects of chemicals and other toxicants on the blood and the hematopoietic system, including bone marrow, circulating blood cells, and related organs such as the spleen. The field encompasses the study of how exposures disrupt blood cell formation and function, and how such effects translate into clinical conditions.

End points include anemia, leukopenia, thrombocytopenia, pancytopenia, abnormal blood cell morphology, and bone marrow suppression. Mechanisms include cytotoxic injury to hematopoietic stem and progenitor cells, interference with DNA synthesis and replication, oxidative stress, disruption of signaling pathways, and immune-mediated damage.

Assessment methods involve clinical hematology (complete blood counts, differential counts, reticulocyte counts), bone marrow biopsy or aspiration, in vitro colony-forming unit assays, animal models, and biomarkers of exposure and effect. Risk assessment considers dose, duration, route, and species extrapolation.

Common hematotoxicants include benzene and its metabolites, certain solvents, and heavy metals such as lead and arsenic; various chemotherapeutic drugs (alkylating agents, antimetabolites) are deliberately hematotoxic; some drugs can cause aplastic anemia or myelodysplasia.

Applications and research include use in regulatory toxicology to set exposure limits, evaluate drug safety, and guide environmental health policies. Current topics include mechanistic understanding of hematopoietic toxicity, identification of early biomarkers, and development of alternative in vitro models.